Contents: Affinity Purified anti-mouse/human/rat Neu polyclonal
Catalog Number: 14-6746
Formulation: 200 µg/ml of rabbit polyclonal IgG in PBS containing 0.1 % sodium azide and 0.2% gelatin.
Storage Conditions: Store at 4°C.
DO NOT FREEZE.
Clone: Polyclonal
Isotype: Rabbit IgG
| Prices for This Product* |
| Cat. No. |
Size |
Price |
Qty |
Action |
*International customers: Please contact your distributor for region specific pricing.
|
|
|
Questions? Please consult our answers to frequently asked questions at
http://www.ebioscience.com/faq.
Description
The polyclonal antibody reacts with mouse, rat, and human Neu; the antibody was raised against a peptide mapping to the carboxy terminus of human Neu (HER2 or ErbB-2). The Neu/HER-2 (also known as EGFR-2 or ErbB-2) is a transmembrane tyrosine kinase receptor and a well-defined tumor antigen. Neu/HER-2 is a shared antigen among multiple tumor types. Patients with HER-2/neu protein-overexpressing breast, ovarian, non-small cell lung, colon, and prostate cancers have been shown to have a pre-existent immune response to Neu/HER-2 (1,2). Neu/HER-2 amplification/overexpression confers more aggressive and malignant characteristics on breast cancer cells. Patients with Neu/HER-2-amplified breast cancer have a worse prognosis than those with normal Neu/HER-2 expression (3).
Applications Reported
For research use only, not for diagnostic or therapeutic use. Purified anti-mo/hu/rat Neu poly has been reported for use in immunoprecipitation, immunoblotting (WB), and immunohistochemical staining.
Applications Tested
Purified anti-mo/hu/rat Neu poly has been tested by immunoblotting (WB). (1:200 starting dilution). It is recommended that this antibody be titrated for optimal performance in the assay of interest.
References
1. Bernhard H, Salazar L, Schiffman K, Smorlesi A, Schmidt B, Knutson KL, Disis ML. Vaccination against the HER-2/neu oncogenic protein. Int J Endocr Relat Cancer 2002 Mar;9(1):33-44.
2. Lohrisch C, Piccart M. HER2/neu as a predictive factor in breast cancer. Clin Breast Cancer 2001 Jul;2(2):129-35; discussion 136-7.
3. Hortobagyi GN. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. Semin Oncol 2001 Dec;28(6 Suppl 18):43-7
Related Products
Cat.
66-P746 Blocking Peptides for anti-mouse/human/rat Neu polyclonal
